[go: up one dir, main page]

CL2018002810A1 - Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. - Google Patents

Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.

Info

Publication number
CL2018002810A1
CL2018002810A1 CL2018002810A CL2018002810A CL2018002810A1 CL 2018002810 A1 CL2018002810 A1 CL 2018002810A1 CL 2018002810 A CL2018002810 A CL 2018002810A CL 2018002810 A CL2018002810 A CL 2018002810A CL 2018002810 A1 CL2018002810 A1 CL 2018002810A1
Authority
CL
Chile
Prior art keywords
antibodies
cross
complement factor
complement
treatment
Prior art date
Application number
CL2018002810A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Karen Sue Christopherson
Tony Sangyoung Byun
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of CL2018002810A1 publication Critical patent/CL2018002810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN PROPORCIONA ANTICUERPOS ANTI-FACTOR BB DEL COMPLEMENTO Y COMPOSICIONES QUE COMPRENDEN LOS ANTICUERPOS. LOS ANTICUERPOS ANTI-BB SON ÚTILES PARA EL TRATAMIENTO DE TRASTORNOS MEDIADOS POR EL COMPLEMENTO. LA PRESENTE DESCRIPCIÓN PROPORCIONA MÉTODOS PARA EL TRATAMIENTO DE TRASTORNOS MEDIADOS POR EL COMPLEMENTO.
CL2018002810A 2016-04-04 2018-10-03 Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. CL2018002810A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
CL2018002810A1 true CL2018002810A1 (es) 2019-03-15

Family

ID=60000646

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002810A CL2018002810A1 (es) 2016-04-04 2018-10-03 Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.

Country Status (23)

Country Link
US (3) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (2) KR102673420B1 (es)
CN (2) CN116790614A (es)
AU (2) AU2017246794B2 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (3) IL311675A (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2018210912A1 (en) * 2017-01-17 2019-08-15 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
CA3085945A1 (en) 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
BR112021026181A2 (pt) * 2019-06-27 2022-02-15 Verseau Therapeutics Inc Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
KR20220057530A (ko) * 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
CA3173325A1 (en) * 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR100445103B1 (ko) 1994-12-09 2004-12-04 임페리얼 컬리지 이노베이션스 리미티드 유전자의동정
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
KR20010015856A (ko) 1997-12-12 2001-02-26 마크로메드 인코퍼레이션 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
KR101624587B1 (ko) 2005-12-20 2016-05-26 에스비아이 바이오테크 가부시키가이샤 항-ｉｌｔ7 항체
AU2008293487A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
KR20100105587A (ko) * 2007-11-08 2010-09-29 제넨테크, 인크. 항-인자 ｂ 항체 및 이들의 용도
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN103665170A (zh) 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
HK1199405A1 (en) 2011-10-27 2015-07-03 Nkt治疗公司 Humanized antibodies to inkt
ES2812849T3 (es) * 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
EP2834271B1 (en) 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
WO2014044793A2 (en) * 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
SG10202104175YA (en) 2014-02-27 2021-06-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Also Published As

Publication number Publication date
KR20240096672A (ko) 2024-06-26
JP7326393B2 (ja) 2023-08-15
JP6967528B2 (ja) 2021-11-17
CO2018010827A2 (es) 2018-11-22
IL295288A (en) 2022-10-01
US20190153079A1 (en) 2019-05-23
MX2018012176A (es) 2019-02-07
MA44878A (fr) 2019-03-13
AU2017246794B2 (en) 2024-07-04
US20240228599A1 (en) 2024-07-11
CN109563158A (zh) 2019-04-02
EP3452510A4 (en) 2020-01-15
CN116790614A (zh) 2023-09-22
KR102673420B1 (ko) 2024-06-07
PE20190209A1 (es) 2019-02-07
SG11201808525UA (en) 2018-10-30
IL311675A (en) 2024-05-01
CR20180529A (es) 2019-03-21
ECSP18082302A (es) 2019-01-31
CN109563158B (zh) 2022-08-09
JP2021191789A (ja) 2021-12-16
WO2017176651A1 (en) 2017-10-12
KR20190003951A (ko) 2019-01-10
EP3452510A1 (en) 2019-03-13
US11851482B2 (en) 2023-12-26
DOP2018000219A (es) 2019-03-31
US10934347B2 (en) 2021-03-02
IL262010A (en) 2018-10-31
MY194603A (en) 2022-12-06
PH12018502137A1 (en) 2019-09-23
NZ747018A (en) 2025-05-02
EA201892225A1 (ru) 2019-09-30
TN2018000341A1 (en) 2020-06-15
AU2024224000A1 (en) 2024-12-19
BR112018070357A2 (pt) 2019-01-29
CA3019332A1 (en) 2017-10-12
US20210221877A1 (en) 2021-07-22
JP2019513726A (ja) 2019-05-30
IL295288B1 (en) 2024-04-01
AU2017246794A1 (en) 2018-10-25
JP2023139289A (ja) 2023-10-03
MX2023007149A (es) 2023-06-28
IL295288B2 (en) 2024-08-01
IL262010B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2019003047A2 (es) Anticuerpos anti-il-33 y usos de los mismos
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CL2019001336A1 (es) Inhibidores de la magl.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016009219A (es) Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr.